GlassScriptPhysician profile
Francis Redican
NPI 1972608222
$3,191.50
in general payments reported to CMS, 2019-2025
25 companies · $719 in 2025
The $719 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $508 · 2021: $364 · 2022: $389 · 2023: $601 · 2024: $331 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,651.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $483.66 | 2020-2025 | Xience Sierra, Diamondback Coronary, Nc Trek Neo |
| Boston Scientific Corporation | $314.07 | 2019-2025 | Rotapro, Filterwire Ez, Mamba |
| Janssen Pharmaceuticals, INC | $270.84 | 2020-2024 | Xarelto |
| Zoll Medical Corporation | $216.77 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.11 | 2019-2025 | Jardiance |
| Abiomed | $179.62 | 2019-2024 | Impella |
| Amgen INC. | $169.09 | 2020-2025 | Repatha |
| Cardiovascular Systems INC. | $147.80 | 2020-2023 | Diamondback Coronary |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $147.10 | 2020-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $139.67 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $137.29 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $114.33 | 2019-2024 | |
| Pfizer INC. | $109.90 | 2022-2025 | |
| Stryker Corporation | $106.09 | 2025 | Artix Mt |
| Teleflex LLC | $89.48 | 2023-2024 | Trapliner, Guideliner, Turnpike |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $65.25 | 2022-2024 | Sotalol Hydrochloride |
| Angiodynamics, INC. | $59.82 | 2020-2021 | |
| Novo Nordisk INC | $52.36 | 2025 | Ozempic, Wegovy |
| Impulse Dynamics (USA) INC. | $43.04 | 2024 | Optimizer |
| Shockwave Medical, INC | $35.09 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Medical L6 Intravascular Lithotripsy (Ivl) Catheter |
| Philips North America LLC | $26.86 | 2025 | Igt Devices Undivided |
| Heartflow, INC. | $23.03 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $21.15 | 2025 | Evkeeza |
| Chiesi USA, INC. | $18.62 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francis Redican listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.